IMMEDIATE IMPLANTS: GRAFT VS NO GRAFT

August 7, 2026 updated by: sema kaya

IMMEDIATE IMPLANTOLOGY: EFFECTS OF BONE GRAFTING ON MANDIBULAR BONE MICROSTRUCTURE USING FRACTAL ANALYSIS

This prospective, randomized, controlled, split-mouth clinical trial aims to evaluate the effect of bone grafting on mandibular bone microstructure following immediate implant placement using fractal analysis of panoramic radiographs. Forty systemically healthy adults requiring bilateral immediate implant placement in the mandibular anterior region will be enrolled. In each participant, one implant site will receive a bone graft (Gen-Os), while the contralateral site will serve as the non-grafted control. Panoramic radiographs obtained during routine postoperative follow-up at 1 and 3 months will be analyzed using ImageJ software to calculate fractal dimension values. The primary outcome is the comparison of fractal dimension values between grafted and non-grafted implant sites. The results are expected to provide evidence regarding the effect of bone grafting on early bone healing and microstructural changes following immediate implant placement.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Adults aged 18 to 40 years. Requiring bilateral immediate implant placement in the mandibular anterior region.

Indication for tooth extraction in the mandibular anterior region. Systemically healthy (ASA I). Adequate bone volume for immediate implant placement. Willing and able to attend the scheduled follow-up visits. Routine panoramic radiographs suitable for fractal analysis. Provided written informed consent.

Exclusion Criteria:

Age younger than 18 years or older than 40 years. Systemic diseases affecting bone metabolism. Uncontrolled diabetes mellitus, osteoporosis, or other metabolic bone disorders.

Current use of bisphosphonates, corticosteroids, immunosuppressive drugs, or other medications affecting bone healing.

Pregnancy or breastfeeding. Active infection at the implant site. Heavy smoking or tobacco use. Previous radiotherapy to the head and neck region. Inadequate bone volume preventing immediate implant placement. Inability to attend follow-up visits. Refusal or inability to provide written informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: BONE GRAFT GROUP
IMMEDIATE IMPLANT SITES RECEIVING GEN-OS BONE GRAFT MATERIAL FOLLOWING TOOTH EXTRACTION. BONE HEALING WILL BE EVALUATED USING FRACTAL ANALYSIS OF ROUTINE PANORAMIC RADIOGRAPHS OBTAINED AT 1 AND 3 MONTHS.
Procedure: BONE GRAFTING
GEN-OS BONE GRAFT MATERIAL WILL BE PLACED IN THE EXTRACTION SOCKET DURING IMMEDIATE IMPLANT PLACEMENT ACCORDING TO THE STUDY PROTOCOL. NO ADDITIONAL EXPERIMENTAL PROCEDURES WILL BE PERFORMED.
Active Comparator: NO BONE GRAFT GROUP
IMMEDIATE IMPLANT SITES WITHOUT BONE GRAFTING FOLLOWING TOOTH EXTRACTION. BONE HEALING WILL BE EVALUATED USING FRACTAL ANALYSIS OF ROUTINE PANORAMIC RADIOGRAPHS OBTAINED AT 1 AND 3 MONTHS.
Other: NO BONE GRAFT
Immediate implant placement without bone grafting following tooth extraction. Bone healing will be evaluated using fractal analysis of routine panoramic radiographs obtained at 1 and 3 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
FRACTAL DIMENSION VALUE MEASURED USING IMAGEJ SOFTWARE
Time Frame: 1 month after immediate implant placement and 3 months after immediate implant placement
Fractal dimension values of the peri-implant bone will be measured on digital panoramic radiographs using ImageJ software. Fractal dimension is a unitless numerical parameter used to assess trabecular bone microstructure. Higher values indicate greater trabecular complexity.
1 month after immediate implant placement and 3 months after immediate implant placement

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CHANGE IN FRACTAL DIMENSION VALUE MEASURED USING IMAGEJ SOFTWARE
Time Frame: 1 month and 3 months after immediate implant placement
Fractal dimension values of the peri-implant bone will be measured on digital panoramic radiographs using ImageJ software. The change in fractal dimension values between the 1-month and 3-month assessments will be evaluated separately for grafted and non-grafted implant sites.
1 month and 3 months after immediate implant placement

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

sema kaya

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

August 4, 2026

First Submitted That Met QC Criteria

August 7, 2026

First Posted (Actual)

August 12, 2026

Study Record Updates

Last Update Posted (Actual)

August 12, 2026

Last Update Submitted That Met QC Criteria

August 7, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • YYU-OMFS-2026-002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe